Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 12/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483396 | 0.87 | MAPT (0.46) | LMNAPDK1 | |
| SCHEMBL4175596 | 0.80 | CASP6 (0.58) | TSHRCASP6HCAR3LMNAAPEX1 | |
| SCHEMBL1367139 | 0.79 | EPHX2 (0.52) | LMNA | |
| SCHEMBL4952365 | 0.79 | HCAR3 (0.47) | TSHRCASP6HCAR3LMNAPDK1 | |
| SCHEMBL9161976 | 0.78 | HTT (0.43) | HCAR3APEX1 | |
| SCHEMBL13264670 | 0.78 | CASP6 (0.55) | TSHRCASP6HCAR3LMNAAPEX1 | |
| SCHEMBL6950169 | 0.78 | CASP6 (0.55) | TSHRCASP6HCAR3LMNAAPEX1 | |
| SCHEMBL8113531 | 0.78 | VCAM1 (0.46) | LMNA | |
| SCHEMBL5468913 | 0.78 | MEN1 (0.60) | TSHRLMNA | |
| SCHEMBL20214261 | 0.77 | HCAR3 (0.44) | TSHRCASP6HCAR3ALOX5PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2014-02-20 | — | — | US | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8318796-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-7576115-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | TSHR 43/4885CASP6 4240/4885HCAR3 374/4885 |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | TSHR 47/4885CASP6 4220/4885HCAR3 355/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | TSHR 44/4885CASP6 4224/4885HCAR3 378/4885 |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | TSHR 43/4885CASP6 4240/4885HCAR3 374/4885 |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | TSHR 43/4885CASP6 4240/4885HCAR3 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.